

Ref: FOI/GS/ID 7203

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

04 February 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to the treatment of dermatological and rheumatological conditions.

You asked:

Q1. How many patients were treated in December 2021 (or latest available month) by the dermatology department with the following drugs:

- 1. Abrocitinib (Cibinqo)*
- 2. Baricitinib (Olmiant)*
- 3. Bimekizumab (Bimzelx)*
- 4. Brodalumab (Kyntheum)*
- 5. Dupilumab (Dupixent)*
- 6. Ixekizumab (Taltz)*
- 7. Risankizumab (Skyrizi)*
- 8. Guselkumab (Tremfya)*
- 9. Secukinumab (Cosentyx)*
- 10. Tildrakizumab (Ilumetri)*
- 11. Tralokinumab (Adtralza)*
- 12. Ustekinumab (Stelara)*

Q2. How many patients were treated in December 2021 (or latest available month) by the rheumatology department with the following drugs:

- 1. Baricitinib (Olmiant)*
- 2. Filgotinib (Jyseleca)*
- 3. Guselkumab (Tremfya)*
- 4. Ixekizumab (Taltz)*
- 5. Risankizumab (Skyrizi)*
- 6. Secukinumab (Cosentyx)*
- 7. Tofacitinib (Xeljanz)*
- 8. Upadacitinib (Rinvoq)*
- 9. Ustekinumab (Stelara)*

Trust response:

Q1. The Trust does not have a Dermatology department.

Q2. The attached and linked report can be used to answer this question.

Please note: Pharmacy Reporting is now by financial month/quarter/year.



April 2021-March
2022 Rheumatology